OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Activity Overview

Welcome to this OncoByte Adaptive Learning Pathway!

Each OncoByte video consists of a 5-minute presentation by our expert faculty on a key foundational topic regarding chemotherapy, CDK4/6 inhibitors, and PARP inhibitors in the adjuvant setting to reduce recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer (HR+/HER2– eBC).

Prior to watching an OncoByte video, you will be asked 2 questions: 1 to assess your baseline knowledge of the topic and 1 to assess your confidence. If you answer the question correctly and indicate high confidence, you may continue to the next topic. If you answer the question incorrectly or without high confidence, you will be directed to watch the accompanying OncoByte video.

After completing your customized learning pathway, you will be led to a panel discussion where our expert faculty will help you synthesize the latest information and data on adjuvant therapy to reduce recurrence risk in patients with HR+/HER2– eBC to help guide your incorporation of these novel treatments into everyday practice.

Target Audience

This educational program is primarily directed toward medical oncologists, surgical oncologists, advanced practice providers, nurses, and pharmacists who are involved in the management of patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess risk factors for recurrence in patients with HR+/HER2– early-stage breast cancer (eBC)
• Evaluate the role of genomic assays and clinical tools to assess recurrence risk in HR+/HER2– eBC
• Analyze the latest clinical trial data related to the use of adjuvant systemic therapies for high-risk, HR+/HER2– eBC
• Develop personalized treatment plans for adjuvant systemic therapy in patients with high-risk HR+/HER2– eBC
• Apply evidence-based strategies to mitigate and manage treatment-related adverse effects in patients receiving systemic adjuvant therapy for HR+/HER2– eBC

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.

In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.

Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.